OIA
ESPR icon

Optimum Investment Advisors’s Esperion Therapeutics ESPR Stock Holding History

Optimum Investment Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$22K – 977
2018
Q3 		$22K Buy
+500
New +$23K 0.01% 701

Other funds holding ESPR

BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Optimum Investment Advisors's ESPR Position: Q4 2018 in Review

Optimum Investment Advisors sold out of Esperion Therapeutics (ESPR) in Q4 2018, closing a stake of 500 shares — an estimated $22K sold.

Optimum Investment Advisors first reported a position in ESPR in Q3 2018 and held it in 1 quarter. The position peaked at $22K in Q3 2018. 156 funds tracked by Wall St. Rank hold ESPR as of Q4 2018.

  • Optimum Investment Advisors reported no remaining Esperion Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Optimum Investment Advisors sold 500 Esperion Therapeutics shares in Q4 2018, an estimated $22K.
  • Optimum Investment Advisors first reported a position in Esperion Therapeutics in Q3 2018 and held it in 1 quarter.
  • Optimum Investment Advisors's Esperion Therapeutics position peaked at $22K in Q3 2018.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2018.

Based on Optimum Investment Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.